Early-Stage Pulmonary Arterial Hypertension Therapy From Pulmokine Awarded $1.5 Million Through Federally Funded VITA Contract
News, PAH News
Rensselaer, New York-based biopharmaceutical company Pulmokine recently made a major announcement regarding the company’s efforts in developing a novel therapy for pulmonary arterial hypertension (PAH). In a press release from late ... Read more